As shown in Fig. S7E, compared with normal cells, luminal or HER2-enriched breast cancer cells, TNBC cells exhibited higher SCD1 and FADS2 expression compared with, which may explain their high sensitivity to combinational treatment of CB1 and ferroptosis inducers. The gene discussed is FADS2; the disease is breast carcinoma.